CD274 and non-small cell lung carcinoma: Recently, the combination of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis (i.e., Nivolumab) with P-doublet chemotherapy in the neoadjuvant setting, showed improved clinical management of patients with resectable NSCLC [9] and gained approval by Food and Drug Administration (FDA).